ABEONA THERAPEUTICS INC. Debt Securities, Available-for-sale, Unrealized Gain
ABEONA THERAPEUTICS INC. (ABEO) reported Debt Securities, Available-for-sale, Unrealized Gain of $138.00 thousand for the 12-month period ending 2025-12-31, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain · last filed 2026-08-13
- ABEONA THERAPEUTICS INC. debt securities, available-for-sale, unrealized gain for the quarter ending 2025-12-31 was $30.00K.
- ABEONA THERAPEUTICS INC. debt securities, available-for-sale, unrealized gain for the quarter ending 2025-09-30 was $89.00K.
- ABEONA THERAPEUTICS INC. debt securities, available-for-sale, unrealized gain for the quarter ending 2024-12-31 was -$21.00K.
- ABEONA THERAPEUTICS INC. debt securities, available-for-sale, unrealized gain for the quarter ending 2022-03-31 was $3.00K.
- ABEONA THERAPEUTICS INC. debt securities, available-for-sale, unrealized gain for fiscal 2024 was $30.00K.
- ABEONA THERAPEUTICS INC. debt securities, available-for-sale, unrealized gain for fiscal 2021 was $9.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain 3 month | Debt Securities, Available-for-sale, Unrealized Gain 6 month | Debt Securities, Available-for-sale, Unrealized Gain 9 month | Debt Securities, Available-for-sale, Unrealized Gain 12 month |
|---|---|---|---|---|
| 2025-12-31 | $30.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-13 | $119.00K derived: sum of 2 quarters · filed 2026-08-13 | $138.00K 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $89.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $108.00K 10-Q · filed 2025-11-12 | ||
| 2025-06-30 | $19.00K 10-Q · filed 2025-08-14 | |||
| 2024-12-31 | -$21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $30.00K 10-K · filed 2026-03-17 | ||
| 2024-09-30 | $51.00K 10-Q · filed 2024-11-14 | |||
| 2022-03-31 | $3.00K 10-Q · filed 2022-05-13 | |||
| 2021-12-31 | $9.00K 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |